Albert Seymour, Ph.D., is the CEO of Q32 Bio and has a strong background in genetics. He completed his B.A. in Biology at the University of Delaware, an M.S. from Johns Hopkins University, and earned a Ph.D. in Human Genetics...

Albert Seymour, Ph.D., is the CEO of Q32 Bio and has a strong background in genetics. He completed his B.A. in Biology at the University of Delaware, an M.S. from Johns Hopkins University, and earned a Ph.D. in Human Genetics from the University of Pittsburgh. His career includes a significant stint as Senior Vice President at Shire, where he focused on global research. Dr. Seymour became the Chief Scientific Officer at Q32 Bio in April 2016 and was promoted to CEO in September 2022. Highly involved in the biotech industry, he has been a key player in developing gene therapies. His total compensation in 2022 was around $1.2 million, which included a salary of $570,000 and a performance-based bonus based on company goals. Notably, he has been a part of partnerships that led to substantial investments, such as a deal with Pfizer that brought about $60 million to the company. Dr. Seymour's leadership continues to shape Q32's direction as it aims to impact genetic therapies significantly.